Review



asunercept  (Apogenix Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Apogenix Inc asunercept
    Asunercept, supplied by Apogenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/asunercept/pmc11541427__mmc1-194-47-33?v=Apogenix+Inc
    Average 90 stars, based on 1 article reviews
    asunercept - by Bioz Stars, 2026-07
    90/100 stars

    Images



    Similar Products

    asunercept  (Apogenix Inc)
    90
    Apogenix Inc asunercept
    Asunercept, supplied by Apogenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/asunercept/pmc11541427__mmc1-194-47-33?v=Apogenix+Inc
    Average 90 stars, based on 1 article reviews
    asunercept - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    asunercept (cd95-fc)  (Apogenix Inc)
    90
    Apogenix Inc asunercept (cd95-fc)
    Patient baseline characteristics and demographics (modified intent-to-treat set).
    Asunercept (Cd95 Fc), supplied by Apogenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/asunercept/pmc11541427-119-0-2?v=Apogenix+Inc
    Average 90 stars, based on 1 article reviews
    asunercept (cd95-fc) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Patient baseline characteristics and demographics (modified intent-to-treat set).

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Patient baseline characteristics and demographics (modified intent-to-treat set).

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques: Modification

    Summary of the Cox-proportional hazard model and comparison between the asunercept and SOC arms using a log-rank test for the time to clinical improvement.

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Summary of the Cox-proportional hazard model and comparison between the asunercept and SOC arms using a log-rank test for the time to clinical improvement.

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques: Comparison

    Kaplan–Meier cumulative rate and its 95% confidence interval for the time to clinical improvement (asunercept all doses versus SOC, mITT set) . mITT, modified intent-to-treat. SOC, standard of care.

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Kaplan–Meier cumulative rate and its 95% confidence interval for the time to clinical improvement (asunercept all doses versus SOC, mITT set) . mITT, modified intent-to-treat. SOC, standard of care.

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques: Modification

    Summary of the Cox-proportional hazard model and comparison of Kaplan–Meier curves between treatment and control groups using a log-rank test for the time to clinical improvement (asunercept all doses versus SOC, mITT set).

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Summary of the Cox-proportional hazard model and comparison of Kaplan–Meier curves between treatment and control groups using a log-rank test for the time to clinical improvement (asunercept all doses versus SOC, mITT set).

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques: Comparison, Control

    Summary of the Cox-proportional hazard model for the time to clinical improvement in the WHO 4 subgroup (mITT set) (342/435 patients; 78.6%).

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Summary of the Cox-proportional hazard model for the time to clinical improvement in the WHO 4 subgroup (mITT set) (342/435 patients; 78.6%).

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques:

    Summary of the Cox-proportional hazard model and comparison of Kaplan–Meier curves between treatment and control groups using a log-rank test for the time to clinical improvement (mITT set).

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Summary of the Cox-proportional hazard model and comparison of Kaplan–Meier curves between treatment and control groups using a log-rank test for the time to clinical improvement (mITT set).

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques: Comparison, Control

    All-Cause Mortality (mITT set).

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: All-Cause Mortality (mITT set).

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques:

    Correlation of lymphocyte counts and asunercept administration. a: 3-day rolling average of the median observed lymphocyte counts stratified by treatment arm. b: Simulation results for plasma asunercept concentrations. c: Simulation results for lymphocyte counts in correlation to asunercept concentrations . Arrows indicate asunercept dosing. (Colour: red = SOC, olive = SOC + 25 mg, green = SOC + 100 mg, blue = SOC + 400 mg).

    Journal: eClinicalMedicine

    Article Title: Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial

    doi: 10.1016/j.eclinm.2024.102879

    Figure Lengend Snippet: Correlation of lymphocyte counts and asunercept administration. a: 3-day rolling average of the median observed lymphocyte counts stratified by treatment arm. b: Simulation results for plasma asunercept concentrations. c: Simulation results for lymphocyte counts in correlation to asunercept concentrations . Arrows indicate asunercept dosing. (Colour: red = SOC, olive = SOC + 25 mg, green = SOC + 100 mg, blue = SOC + 400 mg).

    Article Snippet: Asunercept (CD95-Fc; Apogenix GmbH, Heidelberg, Germany) consists of the extracellular domain of human CD95 fused to the Fc region of human immunoglobulin G1 (IgG1).

    Techniques: Clinical Proteomics